How to actively target tumor sites manipulating the controllable release of the encapsulated anticancer drugs and photosensitizers for synergistic anticancer therapy remains a big challenge. In this study, a cancer cell-targeted, near-infrared (NIR) light-triggered and anticancer drug loaded liposome system (LPs) was developed for synergistic cancer therapy. Photosensitizer indocyanine green (ICG) and chemotherapy drug Curcumin (CUR) were coencapsulated into the liposomes, followed by the surface conjugation of GE11 peptide for epidermal growth factor receptor (EGFR) targeting on the cancer cell surface. Strictly controlled by NIR light, GE11 peptide modified and CUR/ICG-loaded LPs (GE11-CUR/ICG-LPs) could introduce hyperthermia in EGFR overexpressed A549 cancer cells for photothermal therapy, which could also trigger the increased release of CUR for enhanced cancer cell inhibition. GE11-CUR/ICG-LPs synergized photochemotherapy could induce reactive oxygen species (ROS) generation and cytoskeleton disruption to activate stronger apoptotic signaling events than the photothermal therapy or chemotherapy alone by regulating Bax/Bcl-2 and PI3K/AKT pathways. This EGFR-targeted drug-delivery nanosystem with NIR sensitivity may potentially serve in more effective anticancer therapeutics with reduced off-target effects.

中文翻译：

---

GE11肽缀合的脂质体，用于EGFR靶向和化学光热联合抗癌治疗

如何积极地靶向肿瘤部位，以控制包封的抗癌药物和光敏剂的可控释放以进行协同抗癌治疗仍然是一个巨大的挑战。在这项研究中，开发了靶向癌细胞，近红外（NIR）触发和负载抗癌药物的脂质体系统（LPs），用于协同癌症治疗。将光敏剂吲哚菁绿（ICG）和化学治疗药物姜黄素（CUR）共封装到脂质体中，然后将GE11肽表面缀合至靶向癌细胞表面的表皮生长因子受体（EGFR）。在近红外灯的严格控制下，GE11肽修饰的CUR / ICG-LPs（GE11-CUR / ICG-LPs）可以在EGFR过表达的A549癌细胞中引入热疗，以进行光热疗法，这也可能触发CUR释放增加，从而增强癌细胞抑制作用。GE11-CUR / ICG-LPs协同光化学疗法可通过调节Bax / Bcl-2和PI3K / AKT途径来诱导活性氧（ROS）生成和细胞骨架破坏，从而比单独的光热疗法或化学疗法激活更强的凋亡信号事件。这种具有NIR敏感性的EGFR靶向药物递送纳米系统可能具有减少脱靶效应的更有效的抗癌疗法。